<SEC-DOCUMENT>0001213900-23-024636.txt : 20230330
<SEC-HEADER>0001213900-23-024636.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330161022
ACCESSION NUMBER:		0001213900-23-024636
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wearable Devices Ltd.
		CENTRAL INDEX KEY:			0001887673
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER COMMUNICATIONS EQUIPMENT [3576]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262838
		FILM NUMBER:		23780781

	BUSINESS ADDRESS:	
		STREET 1:		5 HA-TNUFA ST.
		CITY:			YOKNE'AM ILLIT
		STATE:			L3
		ZIP:			2066736
		BUSINESS PHONE:		97246185670

	MAIL ADDRESS:	
		STREET 1:		5 HA-TNUFA ST.
		CITY:			YOKNE'AM ILLIT
		STATE:			L3
		ZIP:			2066736
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>ea176025-posam_wearabledev.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As filed with the Securities and Exchange
Commission on March 30, 2023</B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B>Registration No. 333-262838</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>UNITED STATES</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>SECURITIES AND EXCHANGE COMMISSION</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Washington, DC 20549</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>POST-EFFECTIVE AMENDMENT NO. 2</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>WEARABLE DEVICES LTD.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>(Exact name of registrant as specified in
its charter)</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State&nbsp;of&nbsp;Israel</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3873</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not&nbsp;Applicable</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</I><BR>
    <I>incorporation&nbsp;or&nbsp;organization)</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary&nbsp;Standard&nbsp;Industrial</I><BR>
    <I>Classification&nbsp;Code&nbsp;Number)</I></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.&nbsp;Employer</I><BR>
    <I>Identification&nbsp;Number)</I></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5 Ha-Tnufa St.<BR>
Yokne&rsquo;am Illit, 2066736 Israel</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: +972.4.6185670</B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Mudra Wearable, Inc.</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>24A Trolley Square #2203</B> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Wilmington, DE 19806</B> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address,
    including zip code, and telephone number,</I></FONT> </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Name,
    address, including zip code, and telephone</I></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>including
    area code, of registrant&rsquo;s principal executive offices)</I></FONT> </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>number,
    including area code, of agent for service)</I></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><I>Copies to:</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oded Har-Even,
    Esq. </B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reut Alfiah,
    Adv.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Howard Berkenblit, Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sullivan &amp; Worcester LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1633 Broadway </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10019</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel: 212.660.3000</B></P></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Gal Cohen, Adv.</B> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sullivan &amp; Worcester Tel-Aviv (Har-Even
        &amp; Co.)</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HaArba&rsquo;a Towers</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>28 HaArba&rsquo;a St.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>North Tower, 35th floor</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tel-Aviv, Israel 6473925<BR>
    Tel:&nbsp;+972.74.758.0480</B></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Approximate date of commencement of proposed sale to the public:
</B>As soon as practicable after the effective date hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If any of the securities being registered on this form are to be
offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act, check the following box.&nbsp;&#9746; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If this form is filed to register additional securities for an
offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&nbsp;&#9744; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering.&nbsp;&#9744; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering.&nbsp; &#9744; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Emerging growth company&nbsp;&#9746; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards &dagger; provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9746; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &dagger;The term &ldquo;new or revised financial accounting standard&rdquo;
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act
or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a),
may determine.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Explanatory Note</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This Post-Effective Amendment No. 2, or this
Post-Effective Amendment, to the Registration Statement on Form F-1 (File No. 333-262838), or the Registration Statement, is being filed
pursuant to our undertaking in the Registration Statement to update and supplement information contained in the Registration Statement,
as originally declared effective by the Securities and Exchange Commission, or the SEC, on September 12, 2022. The Registration Statement
originally covered an offering, or the Offering, of (A) 3,750,000 units, or Units, each consisting of one ordinary share of the Company,
NIS 0.01 par value per share, or Ordinary Shares, and two warrants to purchase one Ordinary Share each, or each, a Warrant (each with
an initial exercise price of $4.00 per Ordinary Share and an exercise price of $2.00 following the Exercise Price Adjustment, as defined
below), in a firm commitment underwritten offering, at a public offering price of $4.25 per Unit,&nbsp;(B) up to 562,500 additional Ordinary
Shares and/or Warrants to purchase up to 1,125,000 Ordinary Shares, issuable to Aegis Capital Corp., the underwriter in the Offering,
or the Underwriter, solely to cover over-allotments, if any, pursuant to its over-allotment option, which expired on October 27, 2022,
and (C) warrants issued to the Underwriter to purchase up to 187,500 Ordinary Shares, at an exercise price of $5.31 per Ordinary Share,
or the Underwriter&rsquo;s Warrants. This Post-Effective Amendment is being filed to (i) update certain financial information contained
in the Registration Statement, and (ii) cover the sale of Ordinary Shares issuable from time to time upon exercise of such Warrants and
Underwriter&rsquo;s Warrants that remain unexercised as of the date hereof, and include an updated prospectus related to the offering
of Ordinary Shares and Ordinary Shares underlying the Warrants and Underwriter&rsquo;s Warrants that were registered on the Registration
Statement. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We refer to the Ordinary Shares, the Warrants,
and the Ordinary Shares issued or issuable upon exercise of the Warrants, collectively, as the securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 20, 2022, the Company&rsquo;s
volume weighted average stock price was less than the exercise floor of $2.00 for the Warrants. Accordingly, effective after the closing
of trading on December 14, 2022 (the 90th calendar day immediately following the issuance date of the Warrants), the Warrants were adjusted
pursuant to their terms, including, but not limited to, to adjust the exercise price of the Warrants to $2.00, or the Exercise Price
Adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information included in this filing updates
the Registration Statement and the prospectus contained therein, or the Prospectus. No additional securities are being registered under
this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"> <FONT STYLE="color: Red">The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.9pt"> <B>SUBJECT TO COMPLETION,
DATED MARCH 30, 2023</B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Wearable Devices Ltd. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This prospectus relates to the issuance of
up to 8,772,500 ordinary shares, NIS 0.01 par value per share, or Ordinary Shares, of Wearable Devices Ltd., or the Company, upon the
exercise of the following warrants, issued by us on September 15, 2022, as part of our initial public offering, or the IPO: (i) warrants,
or the Warrants, to purchase up to 8,585,000 Ordinary Shares (including Warrants to purchase up to 1,125,000 Ordinary Shares issued following
the partial exercise of the over-allotment option granted to Aegis Capital Corp., or the Underwriter, in connection with the IPO), which
were exercisable at an initial exercise price of $4.00 per Ordinary Share (and an exercise price of $2.00 following the Exercise Price
Adjustment, as defined below), and were exercisable immediately upon issuance and expire on September 15, 2027, and (ii) warrants, or
the Underwriter&rsquo;s Warrants, issued to the Underwriter to purchase up to 187,500 Ordinary Shares, which are exercisable at an exercise
price of $5.31 per Ordinary Share, became exercisable beginning on March 12, 2023 and will expire on September 12, 2027. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> We refer to the Ordinary Shares,
the Warrants, and the Ordinary Shares issued or issuable upon exercise of the Warrants, collectively, as the securities. See &ldquo;Description
of Securities we are Offering&rdquo; for more information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">On September 20, 2022, the Company&rsquo;s volume
weighted average stock price was less than the exercise floor of $2.00 for the Warrants. Accordingly, effective after the closing of
trading on December 14, 2022 (the 90th calendar day immediately following the issuance date of the Warrants), the Warrants were adjusted
pursuant to their terms, including, but not limited to, to adjust the exercise price of the Warrants to $2.00, or the Exercise Price
Adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our Ordinary Shares and Warrants are listed
on the Nasdaq Capital Market, or Nasdaq, under the symbols &ldquo;WLDS&rdquo; and &ldquo;WLDSW,&rdquo; respectively. On March 29, 2023,
the last reported sale price of our Ordinary Shares and Warrants on Nasdaq was $0.53 per share and $0.0985 per warrant, respectively.
See &ldquo;Description of Share Capital &mdash; Warrants&rdquo; for additional information. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">We are an emerging growth company,
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and are subject to reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B>Investing in our securities involves a high
degree of risk.&nbsp;See &ldquo;Risk Factors&rdquo; beginning on page 6 and &ldquo;Item 3. &mdash; Key Information &mdash; D. Risk
Factors&rdquo; in our Annual Report on Form 20-F for the year ended December 31, 2022, or the 2022 Annual Report, incorporated by reference
in this prospectus for a discussion of the factors you should consider carefully before deciding to purchase these securities.</B> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><B>Neither the Securities and Exchange Commission, or the SEC, nor
any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful
or complete.&nbsp;Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023</B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 10%; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
    Summary</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_027">Risk
    Factors</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_028">Cautionary
    Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_029">Listing
    Details</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_030">Use of
    Proceeds</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_032">Capitalization</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_033">Dilution</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_039">Description
    of Share Capital</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_001">Plan of Distribution</A></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> 17 </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_043">Expenses</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_044">Legal
    Matters</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_045">Experts</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_046">Enforceability
    of Civil Liabilities</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_047">Where
    You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#d_001">Incorporation of Certain Information by Reference</A></FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <B>You should rely
only on the information contained in or incorporated by reference into this prospectus and any free writing prospectus prepared by or
on behalf of us or to which we have referred you. We have not authorized anyone to provide you with information that is different. We
are offering to sell the securities, and seeking offers to buy the securities, only in jurisdictions where offers and sales are permitted.
The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus
or any sale of the securities. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>For investors outside
of the United States: Neither we nor the underwriter have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>In this prospectus,
&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Wearable Devices&rdquo; refer to Wearable
Devices Ltd. &ldquo;Mudra&rdquo; is a registered trademark of Wearable Devices Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>All trademarks or
trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade
names in this prospectus are referred to without the&nbsp;<SUP>&reg;</SUP>&nbsp;and&nbsp;<SUP>&trade;</SUP>&nbsp;symbols, but such references
should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
rights thereto. We do not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with,
or endorsement or sponsorship of us by, any other companies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>Our reporting currency
and functional currency is the U.S. dollar.&nbsp;Unless otherwise expressly stated or the context otherwise requires, references in this
prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; mean U.S. dollars.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <B>This prospectus,
including the documents incorporated by reference, includes statistical, market and industry data and forecasts which we obtained from
publicly available information and independent industry publications and reports that we believe to be reliable sources. These publicly
available industry publications and reports generally state that they obtain their information from sources that they believe to be reliable,
but they do not guarantee the accuracy or completeness of the information.</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>We report in accordance
with generally accepted accounting principles in the United States, or U.S. GAAP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_026"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"><I>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully,
including the &ldquo;Risk Factors&rdquo; section and the financial statements and related notes appearing at the end of this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; background-color: white"> We are a growth company
developing a non-invasive neural input interface in the form of a wearable wristband for controlling digital devices using subtle touchless
finger movements. Since our technology was introduced to the market in 2014, we have been working with both business to business, or
B2B, and business to consumer, or B2C, customers as part of our push-pull strategy. We are now in the transition phase from research
and development to commercialization of our technology into B2B products. At the same time, we are in the final stage of manufacturing
our first B2C consumer product, the &ldquo;Mudra Band&rdquo; wristband, an aftermarket accessory band for Apple Watch that allows seamless
control across Apple ecosystem devices such as iPhone, Mac computer, AppleTV, and Pad, inter alia. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our company&rsquo;s vision is to create a world
in which the user&rsquo;s hand becomes a universal input device for touchlessly interacting with technology. We believe that our technology
is setting the standard input interface for the Metaverse. According to an article &ldquo;CES 2021: The Mudra Band and How Wearable Devices
Defining the Future of Immersive Customer Experiences,&rdquo; published in January 2021 by Futurum Research, the Mudra Band has the potential
to bring a whole new level of accessibility and immersive experiences to the wearer of the device. Moreover, according to the article,
what sets the Mudra Band apart from similar technology is its add-on approach to interface with existing commands, as opposed to fixing
the technology into the controlled device. Further, we have generated insights based on dozens of feedbacks we have received for our
technology and learned about the preferred methods of users to produce commands with multiple digital devices, and the Mudra Band incorporates
those preferred methods. We intend to transform interaction and control of digital devices to be as natural and intuitive as real-life
experiences. We imagine a future in which humans can share skills, thoughts, emotions, and movements with each other and with computers,
using wearable interfaces and devices. We believe that neural-based interfaces will become as ubiquitous to interact with wearable computing
and digital devices in the near future as the touchscreen is a universal input method for smartphones.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Combining our own proprietary sensors and AI
(artificial intelligence) algorithms into a stylish wristband, our Mudra platform enables users to control digital devices through subtle
finger movements and hand gestures, without physical touch or contact. These digital devices include consumer electronics, smart watches,
smartphones, AR (augmented reality) glasses, VR (virtual reality) headsets, televisions, personal computers and laptop computers, drones,
robots, etc. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mudra Inspire, our B2B development kit product,
started selling to B2B customers in 2018 as the first point of business engagement and contributed to our early-stage revenues. At CES
2021, the Mudra Band for Apple Watch, our flagship B2C product, won Innovation Award Honoree and the Best Wearable Award. The product
is in its final stages of manufacturing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our early-stage revenues are composed of sales
of our Mudra Inspire and from pilot transactions with several B2B customers. In 2022 and 2021, we had revenues of $45 thousand and $142
thousand, respectively, and comprehensive and net loss of $6.5 million and $2.6 million, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Over 100 companies have purchased our Mudra
Inspire development kit, 30 of which are multinational technology companies. These companies are exploring various input and control
use-cases for their products, ranging over multiple countries and industry sectors, including consumer electronics manufacturers, consumer
electronics brands, electronic components manufacturers, IT (information technology) services and software development companies, industrial
companies, and utility providers. Our objective with these companies is to commercialize the Mudra technology by licensing it for integration
in the hardware and software of these companies&rsquo; products and services. We estimate that there will be a three-to-five-year period
from the time we are first introduced to a customer to signing a licensing agreement. As of March 30, 2023, we have not signed a license
agreement with any of these companies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The core of our platform is Mudra, which means
&ldquo;gesture&rdquo; in Sanskrit language. Mudra&ndash; our Surface Nerve Conductance, or SNC, technology and wristband&mdash;tracks
neural signals on the user&rsquo;s wrist skin surface, which our algorithms decipher to predict as gestures made by finger and hand movements.
The interface binds each gesture with a specific digital function, allowing users to input commands without physical touch or contact.
Mudra gestures are natural to perform, and gestures can be tailored per a user&rsquo;s intent, desired function, and the controlled digital
device. Mudra can detect multiple gesture types, including hand movements, finger movements, and fingertip pressure gradations. In addition
to the control use-case, our Mudra technology and SNC sensor can be utilized in multiple monitoring use-cases where we can monitor neural
and hand movements for digital health purposes, sport analytics performance, and Industry 4.0 solutions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Development Regarding Nasdaq Compliance</B>&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On November&nbsp;25, 2022,
we received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying us that we were
not in compliance with the minimum bid price requirement for continued listing on Nasdaq, as set forth under Nasdaq Listing Rule&nbsp;5550(a)(2),
or the Minimum Bid Price Requirement, because the closing bid price of our Ordinary Shares was below $1.00 per Ordinary Share for the
previous 30 consecutive business days. We were granted 180 calendar days, or until May&nbsp;22, 2023, to regain compliance with the Minimum
Bid Price Requirement. In the event we do not regain compliance with the Minimum Bid Price Requirement by May 22, 2023, we may be eligible
for an additional 180-calendar day grace period. To qualify, we will be required to meet the continued listing requirement for market
value of publicly held shares and all other listing standards for Nasdaq, with the exception of the Minimum Bid Price Requirement, and
will need to provide written notice to The Nasdaq Stock Market LLC of our intent to regain compliance with such requirement during such
second compliance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We intend to monitor the
closing bid price of our Ordinary Shares and may, if appropriate, consider implementing available options to regain compliance with the
minimum bid price requirement, including initiating a reverse stock split. If we do not regain compliance within the allotted compliance
period(s), including any extensions that may be granted, The Nasdaq Stock Market LLC will provide notice that our Ordinary Shares will
be subject to delisting from Nasdaq. At that time, we may appeal The Nasdaq Stock Market LLC&rsquo;s determination to a hearings panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We intend to achieve a leading
brand position for neural input technology, and to expand our operations to digital and wearable computers. Key elements of our growth
strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B>Offer a broad range of platform
                                            devices.</B> We believe everyone&rsquo;s needs are unique, so we will offer our users a wide
                                            range of connected devices to interact and control in multiple styles, form factors, and
                                            price points, to allow people to find the devices that fit their lifestyles and goals. We
                                            believe that we can leverage the growing public acceptance and awareness of wearable neural
                                            technologies and the rising adoption of wearable devices to market multiple Mudra-based consumer
                                            products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B>Introduce new features, use-cases,
                                            software applications, and services.</B> We plan to continue introducing new features and
                                            services to increase user engagement and revenue. For example, we are investing in building
                                            a diverse user-gesture data bank, which will enable us to develop additional new gestures.
                                            It is our belief that the gestures should be natural for the user and tailored based on the
                                            use-case and controlled device, instead of a &ldquo;one size fits all&rdquo; approach which
                                            forces the user to learn new interactions. In addition to the control use-case, our Mudra
                                            technology and SNC sensor can be utilized in multiple monitoring use-cases where we can monitor
                                            neural and hand movements for digital health purposes, sport analytics performance, and Industry
                                            solutions. The platform serves multiple corporations, businesses and individuals in the form
                                            of customized mobile and computer applications with a broad range of business models that
                                            include hardware sales, licensing, and Software-as-a-Service, or SaaS model.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B>Integrate our Mudra technology
                                            into existing devices</B>. We intend to leverage our strong relationships with multiple consumer
                                            electronics companies and brands to sign software and hardware licenses and royalty contracts
                                            to make ourselves a fundamental input component for all digital devices and platforms. We
                                            also believe our superior software and hardware integration ability to work with companies
                                            will enable us to sign agreements with leading global and smaller companies for consumer
                                            devices and industry use-cases.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B>Further penetrate the additional
                                            markets.</B> We intend to increase our focus on building relationships with corporations
                                            in Industry 4.0, wellness and digital health, and sports analytics. Our main advantage is
                                            the ability to continuously and securely track the user&rsquo;s engagement over lengthened
                                            periods of times and supply meaningful insights for employee performance and safety and the
                                            user&rsquo;s physiology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B>Expand brand awareness, global
                                            distribution and drive sales of our products and services.</B> We intend to increase our
                                            marketing efforts to further expand global awareness of our brand and drive greater sales
                                            of our products and services. The international markets represent a significant growth opportunity
                                            for us, and we intend to expand sales of our products and services globally through select
                                            retailers and strategic partnerships.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B>Data monetization</B>. Once
                                            we have a sufficiently large database, we intend to monetize data derived from a combination
                                            of gestures that authenticates a user, identification of patterns of daily behavior, and
                                            monitoring of metrics and identification. This will expand our offerings related to data
                                            and user behavior, which can open multiple new markets and opportunities.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are an Israeli corporation
based in Yokne&rsquo;am Illit, Israel and were incorporated in Israel in 2014 under the name Wearable Devices Ltd. Our principal executive
offices are located at 5 Ha-Tnufa St., Yokne&rsquo;am Illit, 2066736 Israel. Our telephone number in Israel is 972.4.6185670 Our website
address is <I>www.wearabledevices.co.il</I>. The information contained on, or that can be accessed through, our website is not part of
this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</DIV>





<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company </B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white"> We are an &ldquo;emerging
growth company,&rdquo; as defined in Section&nbsp;2(a) of the U.S. Securities Act of 1933, as amended, or the Securities Act, as modified
by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements
applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; such as not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We could remain an
&ldquo;emerging growth company&rdquo; for up to five years, or until the earliest of (a)&nbsp;the last day of the first fiscal year in
which our annual gross revenue exceeds $1.235 billion, (b)&nbsp;the date that we become a &ldquo;large accelerated filer&rdquo; as defined
in Rule&nbsp;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value
of our Ordinary Shares that is held by non-affiliates exceeds $700&nbsp;million as of the last business day of our most recently completed
second fiscal quarter, or (c)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the preceding
three-year period. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of being a Foreign Private Issuer</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to &ldquo;foreign private issuers,&rdquo;
and under those requirements we file reports with the SEC. As a foreign private issuer, we are not subject to the same requirements that
are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects,
are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we are not required to issue quarterly
reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting companies, or individual executive
compensation information that is as detailed as that required of U.S. domestic reporting companies. We also have four months after the
end of each fiscal year to file our annual report with the SEC and are not required to file current reports as frequently or promptly
as U.S. domestic reporting companies. Our officers, directors and principal shareholders are exempt from the requirements to report transactions
in our equity securities and from the short-swing profit liability provisions contained in Section 16 of the Exchange Act. As a foreign
private issuer, we are not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition,
as a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise
required under the Nasdaq Stock Market, or Nasdaq, rules for domestic U.S. issuers. See &ldquo;Risk Factors&mdash;Risks Related to the
Ownership of Our Ordinary Shares.&rdquo; These exemptions and leniencies will reduce the frequency and scope of information and protections
available to you in comparison to those applicable to a U.S. domestic reporting company. We intend to take advantage of the exemptions
available to us as a foreign private issuer during and after the period we qualify as an &ldquo;emerging growth company.&rdquo;</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 61%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wearable Devices Ltd. &nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares currently
        issued</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>and outstanding</B></FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>15,218,845 Ordinary Shares</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares offered by us</B></FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Up to 8,772,500 Ordinary Shares issuable upon the exercise
         of (i) Warrants to purchase up to 8,585,000 Ordinary Shares (including Warrants to purchase up to 1,125,000 Ordinary Shares
         issued following the partial exercise of the over-allotment option granted to the Underwriter, in connection with the IPO),
         and (ii) Underwriter&rsquo;s Warrants to purchase up to 187,500 Ordinary Shares. </P> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Warrants</B></FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Warrant has an exercise price of $4.00 per
    Ordinary Share, became exercisable immediately upon issuance and will expire on September 15, 2027. Subject to certain exemptions
    outlined in the Warrant, for a period until two years from the date of issuance of the Warrant, if the Company shall sell, enter
    into an agreement to sell and subsequently sells, or grant any option to purchase, or sell, enter into an agreement to sell and subsequently
    sells, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase
    or other disposition that subsequently closes) any Ordinary Shares or convertible security, at an effective price per share less
    than the exercise price of the Warrant then in effect, or a Dilutive Issuance, the exercise price of the Warrant shall be reduced
    to equal the effective price per share in such Dilutive Issuance;&nbsp;provided, however, that in no event shall the exercise price
    of the Warrant be reduced to an exercise price lower than 50% of the exercise price of the Warrants on the issuance date, or the
    Initial Exercise Price. On the date that is 90 calendar days immediately following the initial issuance date of the Warrants, the
    exercise price of the Warrants will adjust to be equal to the Reset Price, provided that such value is less than the exercise price
    in effect on that date. The Reset Price is equal to the greater of (a) 50% of the Initial Exercise Price of the Warrants on the issuance
    date or (b) 100% of the lowest volume weighted average price per Ordinary Share occurring on any day between the initial exercise
    date of the Warrants and 90 calendar days following the issuance date of the Warrants. The lowest Reset Price is $2.00, which is
    50% of the Initial Exercise Price. To better understand the terms of the Warrants, you should carefully read the &ldquo;Description
    of Share Capital&rdquo; section of this prospectus. You should also read the form of Warrant, which is filed as an exhibit to the
    registration statement of which this prospectus forms a part. The exercise price adjustments were offered to Warrant holders based
    on market conditions. On September 20, 2022, the Company&rsquo;s volume weighted average stock price was less than the exercise floor
    of $2.00 for the Warrants. Accordingly, effective after the closing of trading on December 14, 2022 (the 90th calendar day immediately
    following the issuance date of the Warrants), the Warrants were adjusted pursuant to their terms, including, but not limited to,
    to adjust the exercise price of the Warrants to $2.00, or the Exercise Price Adjustment.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter&rsquo;s
    Warrants</B></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    issued to the Underwriter Underwriter&rsquo;s Warrants to purchase up to 187,500 Ordinary Shares. The Underwriter&rsquo;s Warrants
    have an exercise price of $5.31 per Ordinary Share, became exercisable beginning on March 12, 2023 and will expire on September 12,
    2027.&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares to be issued and outstanding
    assuming exercise of and outstanding Warrants and Underwriter&rsquo;s Warrants <SUP>(1)</SUP>&nbsp;</B></FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> 23,991,345 Ordinary Shares </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 7pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> We will receive up to approximately $17.2 million in net
         proceeds if all Warrants are exercised (assuming an exercise price of $2.00 per Ordinary Share following the Exercise Price
         Adjustment) and up to $996 thousand in net proceeds if all Underwriter&rsquo;s Warrants are exercised. </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

</DIV>





<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 61%; font-size: 10pt">We currently expect to use the net proceeds from the IPO and this offering for the following purposes: </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 2%">&#9679;</TD>
    <TD STYLE="width: 54%">approximately $1.95 million to manufacture the Mudra Band for Apple Watch product, which includes the purchase of components, manufacturing of components, and assembly of the product;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>approximately $2.4 million to market the Mudra Band for Apple Watch and to market additional future consumer products of our B2C product line;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>approximately $3.3 million for the continued research and development of our Mudra technology, including the research and development of the Mudra XR wristband, and additional neural signals architecture, algorithms and User Experience, or UX;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>approximately $2.1 million for sales and support of our B2B customers, and for the integration and licensing our Mudra technology into our B2B customers&rsquo; products;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &#9679; </TD>
    <TD> $300,000 for a cash payment to Alpha Capital Anstalt, or Alpha, as compensation for their consent to the IPO; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>$840,000 for repayment of a loan from L.I.A. Pure Capital Ltd., or Pure Capital; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>the remainder for working capital and general corporate purposes, including an aggregate of approximately $650 thousand payable to certain of our executive officers as bonuses as a result of completion of the IPO.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 61%">The amounts and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion in the application of the net proceeds of the IPO and this offering.&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <B>Risk factors</B>&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="padding-right: 1.05pt"> Investing in our securities involves a high degree of risk.&nbsp;You should read the
    &ldquo;Risk Factors&rdquo; section starting on page 6 of this prospectus, and &ldquo;Item&nbsp;3. &mdash; Key
    Information&nbsp;&mdash;&nbsp;D.&nbsp;Risk Factors&rdquo; in our 2022 Annual Report, incorporated by reference herein, and other
    information included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before
    deciding to invest in the Ordinary Shares and Warrants.&nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.05pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Nasdaq symbol:&nbsp;</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.05pt">Our Ordinary Shares and Warrants are listed on the Nasdaq under the symbols &ldquo;WLDS&rdquo; and &ldquo;WLDSW,&rdquo; respectively. We do not intend to apply for listing of the Underwriter&rsquo;s Warrants on any securities exchange or other nationally recognized trading system.&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated,
    the number of Ordinary Shares outstanding prior to and after this offering is based on 15,218,845 Ordinary Shares outstanding as
    of March 30, 2023.&nbsp;This number excludes:</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> &#9679;&nbsp; </TD>
    <TD> 1,247,689 Ordinary Shares issuable upon the exercise of options to directors, employees and consultants under our share incentive
    plan, at a weighted average exercise price of $0.55, of which 994,078 were vested as of March 30, 2023;&nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679;&nbsp; </TD>
    <TD> 22,205 Ordinary Shares issuable upon the exercise of warrants issued to a consultant, at an exercise price of $2.25, which
    are all vested as of March 30, 2023, and additional 23,640 Ordinary Shares issuable upon the exercise of warrants issued to an advisor,
    at an exercise price of $4.23 per Ordinary Share;&nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679; &nbsp;</TD>
    <TD>15,760 Ordinary Shares issuable upon the exercise of warrants issued in connection with certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs, at an exercise price of $6.35 per Ordinary Share; &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; &nbsp; </TD>
    <TD> 636,998 Ordinary Shares reserved for future issuance under our 2015 Share Option Plan, or the 2015 Plan; and&nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"> &nbsp; </TD>
    <TD STYLE="padding-right: 1.05pt; font-size: 10pt; width: 24px"> &#9679;&nbsp; </TD>
    <TD STYLE="padding-right: 1.05pt; font-size: 10pt"> 671,687 Ordinary Shares issuable upon the exercise of warrants issued to certain
    investors in April 2021 pursuant to their share purchase agreements with us, at an exercise price of $5.29 per Ordinary Share.&nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_027"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white"> <I>An investment in
our securities involves a high degree of risk. You should carefully consider the risks set forth under the caption &ldquo;Item 3. Key
Information &mdash; D. Risk Factors&rdquo; in our 2022 Annual Report, which is incorporated by reference in this prospectus, or any updates
in our Reports of Foreign Private Issuer on Form 6-K, together with all of the other information appearing in this prospectus or incorporated
by reference into this prospectus before making an investment in our securities. Our business, financial condition or results of operations
could be materially and adversely affected if any of these risks occurs and, as a result, the market price of our securities could decline
and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties.
See &ldquo;Cautionary Statement Regarding Forward-Looking Statements.&rdquo; Our actual results could differ materially and adversely
from those anticipated in these forward-looking statements as a result of certain factors.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="a_028"></A><B>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Some of the statements
made under &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Use of Proceeds,&rdquo; &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations,&rdquo; &ldquo;Business&rdquo; and elsewhere in this prospectus, including
in our 2022 Annual Report incorporated by reference herein, and other information included or incorporated by reference in this prospectus,
constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo; or &ldquo;continue,&rdquo; or the negative
of these terms or other comparable terminology. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">These forward-looking
statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain
projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research,
development, completion and use of our products, and all statements (other than statements of historical facts) that address activities,
events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Important factors that
could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">SNC becoming the industry standard input method for wearable computing and consumer electronics;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to maintain and expand our existing customer base; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to maintain and expand compatibility of our devices with a broad range of mobile devices
    and operating systems;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to maintain our business models;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to correctly predict the market growth;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to remediate material weaknesses in our internal control over financial reporting;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to retain our founders;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to maintain, protect, and enhance our intellectual property;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our ability to raise capital through the issuance of additional securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the impact of COVID-19 and resulting government actions on us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the impact of competition and new technologies;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">general market, political and economic conditions in the countries in which we operate;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">projected capital expenditures and liquidity;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">changes in our strategy; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">litigation; and</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; </TD>
    <TD> those factors referred to in &ldquo;Item 3. Key Information &mdash; D. Risk Factors,&rdquo; &ldquo;Item 4. Information on
    the Company,&rdquo; and &ldquo;Item 5. Operating and Financial Review and Prospects,&rdquo; of our 2022 Annual Report as well
    other factors in the 2022 Annual Report.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt; background-color: white"> These statements are
only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&rsquo;s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. We discuss many of these risks in this prospectus in greater detail under the heading &ldquo;Risk Factors&rdquo; and elsewhere
in this prospectus and the documents incorporated herein by reference. You should not rely upon forward-looking statements as predictions
of future events. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Although we believe that
the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements,
whether as a result of new information, future events or otherwise, after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_029"></A><B>LISTING DETAILS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our Ordinary Shares and Warrants are listed
on Nasdaq under the symbols &ldquo;WLDS&rdquo; and &ldquo;WLDSW,&rdquo; respectively. All of our Ordinary Shares have the same rights
and privileges. See &ldquo;Description of Share Capital.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_030"></A><B>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We
                                            will receive up to approximately $17.2 million in net proceeds if all Warrants are exercised
                                            (assuming an exercise price of $2.00 per Ordinary Share following the Exercise Price Adjustment)
                                            and up to $996 thousand if all Underwriter&rsquo;s Warrants are exercised.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We currently expect to use the net proceeds
from the IPO and this offering for the following purposes: </P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $1.95&nbsp;million to manufacture the Mudra Band for Apple Watch product, which includes
                                            the purchase of components, manufacturing of components, and assembly of the product;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-indent: -15pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $2.4 million to market the Mudra Band for Apple Watch and to market additional future consumer
                                            products of our B2C product line;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-indent: -15pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $3.3 million for the continued research and development of our Mudra technology, including
                                            the research and development of the Mudra XR wristband, and additional neural signals architecture,
                                            algorithms and User Experience, or UX;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $2.1 million for sales and support of our B2B customers, and for the integration and licensing
                                            our Mudra technology into our B2B customers&rsquo; products;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-indent: -15pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">$300,000
                                            for a cash payment to Alpha, as compensation for their consent to the IPO;</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-indent: -15pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$840,000
                                            for repayment of a loan from L.I.A. Pure Capital Ltd., or Pure Capital; and</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            remainder for working capital and general corporate purposes, including an aggregate of approximately
                                            $650 thousand payable to certain of our executive officers as bonuses as a result of completion
                                            of the IPO.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Changing circumstances may cause us to consume
capital significantly faster than we currently anticipate. The amounts and timing of our actual expenditures will depend upon numerous
factors, including&nbsp;the progress of our global marketing and sales efforts, the development efforts and the overall economic environment.
Therefore, our management will retain broad discretion over the use of the proceeds from the IPO and this offering. We may ultimately
use the proceeds for different purposes than what we currently intend. Pending any ultimate use of any portion of the proceeds from the
IPO and this offering, if the anticipated proceeds will not be sufficient to fund all the proposed purposes, our management will determine
the order of priority for using the proceeds, as well as the amount and sources of other funds needed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pending our use of the net proceeds from the
IPO and this offering, we may invest the net proceeds in a variety of capital preservation investments, including short-term, investment
grade, interest bearing instruments and U.S. government securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;</P>





<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_032"></A><B>CAPITALIZATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The following table sets forth our cash and
cash equivalents and our capitalization as of December 31, 2022: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis;</FONT> </TD></TR>
</TABLE>

<P STYLE="margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> on a pro forma basis to give effect to the issuance of
         169,125 Ordinary Shares issued to Alpha and certain other investors on February 16, 2023 under their April 2021 share purchase
         agreements with us following the Exercise Price Adjustment. </P> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma as adjusted basis to give effect
    to the issuance of: (i) up to 8,585,000 Ordinary Shares issuable upon the exercise of the Warrants, for aggregate net proceeds of
    $17.2 million (assuming an exercise price of $2.00 per Ordinary Share following the Exercise Price Adjustment); and (ii) up to 187,500
    Ordinary Shares issuable upon the exercise of the Underwriter&rsquo;s Warrants, for aggregate net proceeds of $996 thousand.</FONT> </TD></TR>
  </TABLE>
<P STYLE="margin: 0"> <FONT STYLE="font-size: 6pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> You should read this table in conjunction with
&ldquo;Item&nbsp;5. Operating and Financial Review and Prospects&rdquo; and our financial statements and related notes included in our
2022 Annual Report, incorporated by reference herein. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> As of December 31, 2022 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"> U.S. dollars in thousands </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma* </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Pro Forma<BR>
 As Adjusted* </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%"> Cash </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 10,373 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 10,373 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 28,539 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Long term debt </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 94 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 94 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 94 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shareholders&rsquo; equity: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Share capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 43 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 44 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 70 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Additional paid in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 23,346 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 23,498 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 41,638 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Accumulated losses </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (13,409 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (13,562 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (13,562 </TD><TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Total shareholders&rsquo; equity </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,980 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,980 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 28,146 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Total capitalization </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 9,980 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 9,980 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 28,146 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> *Unaudited </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The number of Ordinary Shares held by existing
shareholders is based on 15,049,720 Ordinary Shares outstanding as of December 31, 2022, and excludes as of such date: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> &#9679;&nbsp; </TD>
    <TD> 1,247,689 Ordinary Shares issuable upon the exercise of options to directors, employees and consultants under our share incentive
    plan, at a weighted average exercise price of $0.55, of which 994,078 were vested as of March 30, 2023; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679;&nbsp; </TD>
    <TD> 22,205 Ordinary Shares issuable upon the exercise of warrants issued to a consultant at an exercise price of $2.25, which
    are all vested as of March 30, and additional 23,640 Ordinary Shares issuable upon the exercise of warrants issued to an advisor,
    at an exercise price of $4.23 per Ordinary Share; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; &nbsp; </TD>
    <TD> 15,760 Ordinary Shares issuable upon the exercise of warrants, at an exercise price of $6.35 per Ordinary Share, issued in
    connection with certain equity investment agreements, which we refer to as Simple Agreements for Future Equity, or SAFEs; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; &nbsp; </TD>
    <TD> 636,998 Ordinary Shares reserved for future issuance under the 2015 Plan; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; &nbsp; </TD>
    <TD> 671,687 Ordinary Shares issuable upon the exercise of warrants issued to certain investors in April 2021 pursuant to their
    share purchase agreements with us, at an exercise price of $5.29 per Ordinary Share; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 48px"> &nbsp; </TD>
    <TD STYLE="padding-right: 1.05pt; font-size: 10pt; width: 24px"> &#9679; &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> 169,125 Ordinary Shares issued to Alpha and certain other investors on February 16, 2023 under their
    April 2021 share purchase agreements with us following the Exercise Price Adjustment. </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_033"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If you invest in our securities, your interest
will be diluted immediately to the extent of the difference between the price per Ordinary Share you will pay upon exercise of the Warrants
and the pro forma as adjusted net tangible book value per Ordinary Share after exercise of all the Warrants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> On December 31, 2022, we had a negative net
tangible book value of $10.0 million corresponding to a net tangible book value of $0.66 per Ordinary Share. Net tangible book value
per Ordinary Share represents the amount of our total tangible assets less our total liabilities, divided by 15,049,720, the total number
of Ordinary Shares issued and outstanding on December 31, 2022. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Our pro forma net tangible book value as of
December 31, 2022 was approximately $10.0 million, representing approximately $0.65 per Ordinary Share. Pro forma net tangible book value
per Ordinary Share represents the amount of our total tangible assets less our total liabilities, divided by 15,218,845 the total number
of Ordinary Shares issued and outstanding at December 31, 2022, after giving effect to the issuance of 169,125 Ordinary Shares issued
to Alpha and certain other investors on February 16, 2023 under their April 2021 share purchase agreements with us following the Exercise
Price Adjustment. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> After giving effect to the issuance of up to
8,585,000 Ordinary Shares issued upon the exercise of the Warrants, for aggregate net proceeds of $17.2 million (assuming an exercise
price of $2.00 per Ordinary Share following the Exercise Price Adjustment), and the exercise of the Underwriter&rsquo;s Warrants, our
pro forma as adjusted net tangible book value estimated at December 31, 2022 would have been approximately $28.1 million, representing
$1.17 per Ordinary Share. This represents an immediate increase in historical net tangible book value of $0.52 per Ordinary Share to
existing shareholders and an immediate average dilution in net tangible book value of $0.90 per Ordinary Share to purchasers of Ordinary
Shares in this offering.&nbsp;Dilution for this purpose represents the difference between the average price per Ordinary Share paid by
these purchasers and net tangible book value per Ordinary Share immediately after the completion of this offering.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table illustrates this dilution
on a per Ordinary Share basis to investors in this offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"> Exercise price per Warrant </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 2.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Exercise price per Underwriter&rsquo;s Warrant </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 5.31 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Pro Forma net tangible book value per Ordinary Share as of December 31, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.65 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Increase in net tangible book value per Ordinary Share attributable to new investors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.52 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Pro Forma as adjusted net tangible book value per Ordinary Share after this offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.17 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Dilution per Ordinary Share to new investors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.90 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Percentage of dilution in net tangible book value per Ordinary Share for new investors </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 43.3 </TD><TD STYLE="text-align: left"> % </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_039"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SHARE CAPITAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following description of the share capital
of Wearable Devices Ltd., or the Company, and the provisions of our articles of association&nbsp;<FONT STYLE="background-color: white">and
Israeli law</FONT>&nbsp;are summaries, do not purport to be complete and is qualified in its entirety by reference to our articles of
association, Israeli law and any other documents referenced. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Type and class of securities</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Ordinary Shares</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 30, 2023, our authorized share
capital consists of 50,000,000 Ordinary Shares, NIS 0.01 par value per share, of which 15,218,845 Ordinary Shares were issued and outstanding
as of such date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> All of our outstanding Ordinary Shares have
been validly issued, fully paid and non-assessable. Our Ordinary Shares are not redeemable and are not subject to any preemptive right. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our Ordinary Shares and warrants have been
listed on the Nasdaq Capital Market under the symbol &ldquo;WLDS&rdquo; and &ldquo;WLDSW,&rdquo; respectively, since September 13, 2022.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Warrants and Options</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 30, 2023, we have issued and outstanding
Warrants to purchase an aggregate of 8,585,000 Ordinary Shares, with exercise price of $2.00 per Ordinary Share. The Warrants were issued
as part of our IPO and have been listed on the Nasdaq Capital Market under the symbol &ldquo;WLDSW&rdquo; since September 13, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of March 30, 2023, we have 1,247,689 Ordinary
Shares issuable upon the exercise of outstanding options to certain employees, directors and consultants, under our 2015 Share Option
Plan. Additional 636,998 Ordinary Shares are reserved for future issuance under our 2015 Share Option Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Articles of Association</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Directors</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our board of directors shall direct our policy
and shall supervise the performance of our Chief Executive Officer and his actions. Our board of directors may exercise all powers that
are not required under the Israeli Companies Law 5759-1999, or the Companies Law, or under our articles of association to be exercised
or taken by our shareholders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Rights Attached to Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Ordinary Shares shall confer upon the holders
thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px">&#9679;</TD>
    <TD STYLE="text-align: left">equal right to attend and to vote at all of our general meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which attend the meeting and participate at the voting, either in person or by a proxy or by a written ballot, to one vote;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left">equal right to participate in distribution of dividends, if any, whether payable in cash or in bonus shares, in distribution of assets or in any other distribution, on a per share pro rata basis; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left">equal right to participate, upon our dissolution, in the distribution of our assets legally available for distribution, on a per share pro rata basis.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to our articles of association, our
directors are elected by the general meeting and, unless appointed for a shorter term, serve in office until the third annual general
meeting after the general meeting in which such director was appointed, in which such later annual general meeting the directors will
be brought for re-election or replacement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In each annual general meeting, only one director
whose service term lapsed will be deemed retired and brought for re-election, and all other directors whose service term lapsed shall
be deemed to have been re-elected for a term until the next annual general meeting. The director to be deemed and to be re-elected is
the director that served the longest period since its appointment or last re-election. If more than one director served the longest time,
the board of directors will decide which of such directors will be brought for re-election at the relevant general meeting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Annual and Special Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Israeli law, we are required to hold
an annual general meeting of our shareholders once every calendar year, at such time and place which shall be determined by our board
of directors, that must be no later than 15 months after the date of the previous annual general meeting. All meetings other than the
annual general meeting of shareholders are referred to as special general meetings. Our board of directors may call special meetings whenever
it sees fit and upon the request of: (a) any two of our directors or such number of directors equal to one quarter of the directors then
at office; and/or (b) one or more shareholders holding, in the aggregate, (i) 5% or more of our outstanding issued shares and 1% of our
outstanding voting power or (ii) 5% or more of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the provisions of the Companies Law
and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of
record on a date to be decided by the board of directors, which may be between four and forty days prior to the date of the meeting. Resolutions
regarding the following matters must be passed at a general meeting of our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> &#9679; </TD>
    <TD STYLE="text-align: justify"> amendments to our articles of association; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: left">the exercise of our board of directors&rsquo; powers by a general meeting if our board of directors
    is unable to exercise its powers and the exercise of any of its powers is required for our proper management;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&#9679;</TD>
    <TD STYLE="text-align: left">appointment or termination of our auditors;</TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 48px"> &nbsp; </TD>
    <TD STYLE="text-align: left; width: 24px"> &#9679; </TD>
    <TD STYLE="text-align: left"> appointment of directors, including external directors (other than with respect to circumstances
    specified in our articles of association); </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"> &nbsp; </TD>
    <TD STYLE="text-align: left"> &#9679; </TD>
    <TD STYLE="text-align: left"> approval of acts and transactions requiring general meeting approval pursuant to the provisions of
    the Companies Law (mainly certain related party transactions) and any other applicable law; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; </TD>
    <TD STYLE="text-align: justify"> increases or reductions of our authorized share capital; and </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; </TD>
    <TD STYLE="text-align: justify"> a merger (as such term is defined in the Companies Law). </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Notices</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Companies Law require that a notice of
any annual or special shareholders meeting be provided at least 21 days prior to the meeting, and if the agenda of the meeting includes
the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, approval
of the company&rsquo;s general manager to serve as the chairman of the board of directors or an approval of a merger, notice must be
provided at least 35 days prior to the meeting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Quorum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As permitted under the Companies Law, the quorum
required for our general meetings consists of at least two shareholders present in person, by proxy, written ballot or voting by means
of electronic voting system, who hold or represent between them at least 25% of the total outstanding voting rights. If within half an
hour of the time set forth for the general meeting a quorum is not present, the general meeting shall stand adjourned the same day of
the following week, at the same hour and in the same place, or to such other date, time and place as prescribed in the notice to the shareholders
and in such adjourned meeting, if no quorum is present within half an hour of the time arranged, any number of shareholders participating
in the meeting, shall constitute a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
a special general meeting was summoned following the request of a shareholder, and within half an hour a legal quorum shall not have
been formed, the meeting shall be canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Adoption
of Resolutions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our articles of association provide that resolutions
amending provisions of the articles of association related to the staggered board of directors and the composition of the board of directors,
as well as a resolution to dismiss a director, will require an affirmative vote of 70% of the voting power represented at a general meeting
and voting thereon. Other than that, and unless otherwise required under the Companies Law and our articles, all resolutions of the Company&rsquo;s
shareholders require a simple majority vote. A shareholder may vote in a general meeting in person, by proxy, by a written ballot. </P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Changing
Rights Attached to Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unless
otherwise provided by the terms of the shares and subject to any applicable law, any modification of rights attached to any class of
shares must be adopted by the holders of a majority of the shares of that class present a general meeting of the affected class or by
a written consent of all the shareholders of the affected class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights attached
to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Limitations
on the Right to Own Securities in Our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> There are no limitations on the right to own
our securities in our articles of association. In certain circumstances the Warrants have restrictions upon the exercise of such warrants
if such exercise would result in the holders thereof owning more than 4.99% or 9.99% of our Ordinary Shares upon such exercise, as further
described below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Provisions
Restricting Change in Control of Our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our articles of association provide for a staggered
board of directors, which mechanism may delay, defer or prevent a change of control of the Company&rsquo;s board of directors. Other
than that, there are no specific provisions of our articles of association that would have an effect of delaying, deferring or preventing
a change in control of the Company or that would operate only with respect to a merger, acquisition or corporate restructuring involving
us. However, as described below, certain provisions of the Companies Law may have such effect. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Companies Law includes provisions that
allow a merger transaction and requires that each company that is a party to the merger have the transaction approved by its board of
directors and, unless certain requirements described under the Companies Law are met, a vote of the majority of shareholders, and, in
the case of the target company, also a majority vote of each class of its shares. For purposes of the shareholder vote of each party,
unless a court rules otherwise, the merger will not be deemed approved if shares representing a majority of the voting power present
at the shareholders meeting and which are not held by the other party to the merger (or by any person or group of persons acting in concert
who holds 25% or more of the voting power or the right to appoint 25% or more of the directors of the other party) vote against the merger.
If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the controlling shareholder has a
personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary
transactions with controlling shareholders. Upon the request of a creditor of either party to the proposed merger, the court may delay
or prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger the surviving company will
be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of
at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the value of the parties to the merger and the consideration offered to the shareholders. In addition, a merger may
not be completed unless at least (1) 50 days have passed from the time that the requisite proposals for approval of the merger were filed
with the Israeli Registrar of Companies by each merging company and (2) 30 days have passed since the merger was approved by the shareholders
of each merging company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The term &ldquo;Special Majority&rdquo; hereof
will be defined as described in section 275(a)(3) of the Companies Law as: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> &#9679; </TD>
    <TD STYLE="font-size: 10pt"> at least a majority of the shares held by shareholders who are not controlling shareholders and do
    not have personal interest in the merger (excluding a personal interest that did not result from the shareholder&rsquo;s relationship
    with the controlling shareholder) have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered);
    or </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &#9679; </TD>
    <TD STYLE="font-size: 10pt"> the total number of shares voted against the merger, does not exceed 2% of the aggregate voting rights
    of the company. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law also provides that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by
means of a &ldquo;special&rdquo; tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more
of the voting rights in the company, unless there is already another holder of at least 25% or more of the voting rights in the company
or (2) the purchaser would become a holder of 45% or more of the voting rights in the company, unless there is already a holder of more
than 45% of the voting rights in the company. These requirements do not apply if, in general, the acquisition (1) was made in a private
placement that received shareholders&rsquo; approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting
rights in the company which resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was
from a holder of more than 45% of the voting rights in the company which resulted in the acquirer becoming a holder of more than 45%
of the voting rights in the company. A &ldquo;special&rdquo; tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo;
tender offer may be consummated only if (1) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be
acquired by the offeror and (2) the offer is accepted by a majority of the offerees who notified the company of their position in connection
with such offer (excluding the offeror, controlling shareholders, holders of 25% or more of the voting rights in the company or anyone
on their behalf, or any person having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted,
then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity
may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target
company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an
offer or merger in the initial special tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli company&rsquo;s outstanding shares or of
certain class of shares, the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the
outstanding shares of such class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not
tendered in the tender offer and more than half of the offerees who have no personal interest in the offer tendered their shares, all
the shares that the acquirer offered to purchase will be transferred to it by operation of law. However, a tender offer will also be
accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of shares. Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the
tender offer or not, may request, by petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii)
that the fair value should be paid as determined by the court, for a period of six months following the acceptance thereof. However,
the acquirer is entitled to stipulate, under certain conditions, that tendering shareholders will forfeit such appraisal rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lastly,
Israeli tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less favorably
than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his Ordinary Shares
for shares in another corporation to taxation prior to the sale of the shares received in such stock-for-stock swap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Changes
in Our Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
general meeting may, by a simple majority vote of the shareholders attending the general meeting:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> increase our registered share capital by the creation of new
    shares from the existing class or a new class, as determined by the general meeting; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> cancel any registered share capital which have not been taken
    or agreed to be taken by any person; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">consolidate and divide all or any of our share capital into shares
    of larger nominal value than our existing shares;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">subdivide our existing shares or any of them, our share capital or
    any of it, into shares of smaller nominal value than is fixed; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce our share capital and any fund reserved for capital redemption in any manner, and with and subject to any incident authorized, and consent required, by the Companies Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><I>Exclusive Forum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Our articles of association provide that unless
the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America
shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act&nbsp;of
1933, as amended, or the Securities Act and that any person or entity purchasing or otherwise acquiring any interest in any security
of the Company, shall be deemed to have notice of and consented to this exclusive forum provision. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"> <B><I>Staggered Board</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Our articles of association provide for a
split of the board of directors into three classes with staggered three-year terms. At each annual general meeting of our shareholders,
the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will
be for a term of office that expires on the third annual general meeting following such election or re-election, such that each year
the term of office of only one class of directors will expire. The director whom is to be retired and re-elected shall be the director
that served the longest period since its appointment or last re-election or, if more than one director served the longest time, or if
a director who is not to be re-elected agrees to be re-elected, the meeting of the board of directors which sets the date and agenda
for the annual general meeting (acting by a simple majority) will decide which of such directors will be brought for re-election at the
relevant general meeting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following summary of certain terms and
provisions of the Warrants and is subject to, and qualified in its entirety by, the provisions of the warrant agent agreement between
us and VStock Transfer, LLC, as warrant agent, and the form of Warrant, both of which are filed as exhibits to the 2022 Annual Report. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Exercisability</I></B><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Warrants are exercisable at any time after
their original issuance and at any time up to the date that is five&nbsp;years after their original issuance. The Warrants will be exercisable,
at the option of each holder, in whole or in part by delivering to the Company a duly executed exercise notice and, at any time a registration
statement registering the issuance of the Ordinary Shares underlying the Warrants under the Securities Act is effective and available
for the issuance of such shares, by payment in full in immediately available funds for the number of Ordinary Shares purchased upon such
exercise. If a registration statement registering the issuance of the Ordinary Shares underlying the Warrants under the Securities Act
is not effective or available the holder may, in its sole discretion, elect to exercise the Warrant through a cashless exercise, in which
case the holder would receive upon such exercise the net number of Ordinary Shares determined according to the formula set forth in the
Warrant. No fractional shares will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the Company
will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Exercise Limitation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> A holder will not have the right to exercise
any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of Ordinary
Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the
terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided
that any increase in such percentage shall not be effective until 61&nbsp;days following notice from the holder to the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The exercise price per
whole Ordinary Share purchasable upon exercise of the Warrants $4.00 per share. The exercise price is subject to appropriate adjustment
in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting
our Ordinary Shares and also upon any distributions of assets, including cash, stock or other property to our shareholders. Subject to
certain exemptions outlined in the Warrant, for a period until two years from the date of issuance of the Warrant, if the Company shall
sell, enter into an agreement to sell and subsequently sells, or grant any option to purchase, or sell, enter into an agreement to sell
and subsequently sells, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option
to purchase or other disposition the subsequently closes) any Ordinary Shares or convertible security, at an effective price per share
less than the exercise price of the Warrant then in effect, the exercise price of the Warrant shall be reduced to equal the effective
price per share in such Dilutive Issuance;&nbsp;provided, however, that in no event shall the exercise price of the Warrant be reduced
to an exercise price lower than 50% of the Initial Exercise Price. On the date that is 90 calendar days immediately following the initial
issuance date of the Warrants, the exercise price of the Warrants will adjust to be equal to the Reset Price, provided that such value
is less than the exercise price in effect on that date. The Reset Price is equal to the greater of (a) 50% of the Initial Exercise Price
of the Warrants on the issuance date or (b) 100% of the lowest volume weighted average price per Ordinary Share occurring on any day between
the initial exercise date of the Warrants and 90 calendar days following the issuance date of the Warrants. The lowest Reset Price is
$2.00, which is 50% of the Initial Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2022, the Company&rsquo;s volume weighted average stock price was less than the exercise floor of $2.00 for the Warrants.
Accordingly, effective after the closing of trading on December 14, 2022 (the 90th calendar day immediately following the issuance date
of the Warrants), the Warrants were adjusted pursuant to their terms, including, but not limited to, to adjust the exercise price of
the Warrants to $2.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Transferability</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Subject to applicable laws, the Warrants may
be offered for sale, sold, transferred or assigned without the Company&rsquo;s consent. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Warrant Agent</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The Warrants were issued in registered form
under a warrant agent agreement between VStock Transfer, LLC, as warrant agent, and the Company. The Warrants were initially represented
only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company, or DTC,
and registered in the name of Cede&nbsp;&amp; Co., a nominee of DTC, or as otherwise directed by DTC. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Fundamental Transactions</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> In the event of a fundamental transaction, as
described in the Warrants and generally including any reorganization, recapitalization or reclassification of the Ordinary Shares, the
sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into
another person, the acquisition of more than 50% of the Company&rsquo;s outstanding Ordinary Shares, or any person or group becoming
the beneficial owner of 50% of the voting power represented by the Company&rsquo;s outstanding Ordinary Shares, the holders of the Warrants
will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders
would have received had they exercised the Warrants immediately prior to such fundamental transaction without regard to any limitations
on exercised contained in the Warrants.&nbsp;The holders of the Warrants may also require the Company or any successor entity to purchase
the Warrants from the holders by paying to the holder an amount in cash (or other types or form of consideration in special circumstances
listed in the Warrant) equal to the Black Scholes value of the remaining unexercised portion of the Warrant on the date of the fundamental
transaction. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B><I>Home Country Practice</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">For so long as any of the Warrants remains outstanding,
the Company will elect to follow home country practice in lieu of any rules and regulations of the trading market that would limit the
Company&rsquo;s ability to effect the provisions of the Warrants, including but not limited to shareholder approval rules related to the
issuance of securities or adjustment of terms of this Warrant for the benefit of warrant holders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> <B><I>Rights as a Stockholder</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Except as otherwise provided in the Warrants
or by virtue of such holder&rsquo;s ownership of the Company&rsquo;s Ordinary Shares, the holder of a Warrant does not have the rights
or privileges of a holder of the Company&rsquo;s Ordinary Shares, including any voting rights, until the holder exercises the Warrant. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Governing Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I> </I>The Warrants and the warrant
agent agreement are governed by New&nbsp;York law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Underwriter&rsquo;s Warrants</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The following summary of certain terms and provisions
of the Underwriter&rsquo;s Warrant, is subject to, and qualified in its entirety by, the provisions of the form of Underwriter&rsquo;s
Warrant which was filed as an exhibit to the 2022 Annual Report. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> As part of our IPO on the Nasdaq Capital Market,
we issued the Underwriter&rsquo;s warrant to the underwriter. The Underwriter&rsquo;s Warrants are exercisable at $5.31 per Ordinary
Share,&nbsp;became exercisable beginning on March 12, 2023 and will expire on September 12, 2027. The Underwriter&rsquo;s Warrants have
been deemed compensation by FINRA and were therefore subject to a six-month lock-up&nbsp;pursuant to Rule&nbsp;5110 of FINRA.&nbsp;Furthermore,
such Underwriter&rsquo;s Warrants shall be exercisable on a cash basis, provided that if a registration statement registering the ordinary
shares underlying the Underwriter&rsquo;s Warrants is not effective, the Underwriter&rsquo;s Warrants may be exercised on a cashless
basis and have anti-dilution terms that are consistent with FINRA Rule 5110(g)(8)(E) and (F). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="b_001"></A>PLAN OF DISTRIBUTION</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> This prospectus relates to the issuance of up
to 8,772,500 Ordinary Shares upon the exercise of the following warrants, issued by us on September 15, 2022 as part of our IPO: (i)
Warrants to purchase up to 8,585,000 Ordinary Shares (including Warrants to purchase up to 1,125,000 Ordinary Shares issued following
the partial exercise of the over-allotment option granted to the Underwriter, in connection with the IPO) , and (ii) Underwriter&rsquo;s
Warrants issued to the Underwriter to purchase up to 187,500 Ordinary Shares. The ongoing offer and sale by us of the Ordinary Shares
issuable upon exercise of the Warrants and Underwriter&rsquo;s is being made pursuant to this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> We will deliver Ordinary Shares upon exercise
of the Warrants and Underwriter&rsquo;s Warrants. We will not issue fractional Ordinary Shares. Each Warrant contains instructions for
the exercise of such Warrant. In order to exercise a Warrant, the holder must deliver the information required by the applicable warrant
agreement, along with payment of the exercise price, if the exercise price is being paid in cash, for the Ordinary Shares to be purchased.
We will then deliver our Ordinary Shares in the manner described in the applicable warrant agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Aegis Capital Corp., or Aegis, acted as the
sole book-running manager of the IPO. Under the terms of an underwriting agreement we entered with Aegis dated September 12, 2022, we
granted Aegis an option to purchase from us, at the public offering price, less the underwriting discounts and commissions, up to 562,500
additional Ordinary Shares and/or up to 1,125,000 over-allotment Warrants, which expired on October 27, 2022, to cover over-allotments,
if any. On September 13, 2022, the Underwriter partially exercised the over-allotment option with respect to Warrants to purchase up
to 1,125,000 Ordinary Shares. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As additional compensation to Aegis, we issued
to Aegis Underwriter&rsquo;s Warrants to purchase up to 187,500 Ordinary Shares (5.0% of the number of Ordinary Shares issued in the
IPO), at an exercise price per share equal to $5.31 (125.0% of the IPO price). The Underwriter&rsquo;s Warrants and the underlying Ordinary
Shares will not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put,
or call transaction that would result in the effective economic disposition of the Underwriter&rsquo;s Warrants by any person for a period
of 180 days beginning on the date of commencement of sales of the offering in compliance with FINRA Rule 5110. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> The Underwriter&rsquo;s Warrants became exercisable
from the date that is six months from the commencement of the sales of the offering, or March 12, 2023, and will expire four years and
six months after such date, or September 12, 2027, in compliance with FINRA Rule 5110(g)(8)(A). Furthermore, such Underwriter&rsquo;s
Warrants shall be exercisable on a cash basis, provided that if a registration statement registering the ordinary shares underlying the
Underwriter&rsquo;s Warrants is not effective, the Underwriter&rsquo;s Warrants may be exercised on a cashless basis and have anti-dilution
terms that are consistent with FINRA Rule 5110(g)(8)(E) and (F). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for the period ending eighteen (18) months from the closing of the offering, we or any of our subsidiaries (a) decides to finance or
refinance any indebtedness, Aegis (or any affiliate designated by Aegis) shall have the right to act as sole book-runner, sole manager,
sole placement agent or sole agent with respect to such financing or refinancing; or (b) decides to raise funds by means of a public
offering or a private placement or any other capital raising financing of equity, equity-linked or debt securities, Aegis (or any affiliate
designated by Aegis) shall have the right to act as sole book-running manager, sole underwriter or sole placement agent for such financing.
If Aegis or one of its affiliates decides to accept any such engagement, the agreement governing such engagement will contain, among
other things, provisions for customary fees for transactions of similar size and nature.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to indemnify Aegis, its affiliates,
and each person controlling Aegis against any losses, claims, damages, judgments, assessments, costs, and other liabilities, as the same
are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of the IPO undertaken in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Aegis may in the future provide us and our affiliates
with such services. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> In connection with our IPO, we entered into
an underwriting agreement with Aegis pursuant to which we paid Aegis an aggregate of $1,275,000 in commissions and non-accountable expenses.
In addition, we issued Aegis warrants to purchase five percent (5%) of the Ordinary Shares issued in the IPO at an exercise price per
share equal to 125% of the public offering price. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> <B>Offer Restrictions Outside the United States</B> </P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> Other than in the United States, no action has
been taken by us or the underwriter that would permit a public offering of the securities offered by this prospectus in any jurisdiction
where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly,
nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities
be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules
and regulations of that jurisdiction. Persons who come into possession of this prospectus are advised to inform themselves about and
to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an
offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer
or a solicitation is unlawful. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <A NAME="a_043"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPENSES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Set forth below is an itemization of the total
expenses, incurred and paid in connection with the offer and sale of our securities by us pursuant to the IPO and including the securities
remaining covered by this prospectus.&nbsp;With the exception of the SEC registration fee and the FINRA filing fee, all amounts are estimates: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 89%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,462.30</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nasdaq listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">75,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,193.05</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer agent fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and officers insurance</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">495,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printer fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">650,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting and professional fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">422,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58,000.00</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,745,655.35</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <A NAME="a_044"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Certain legal matters concerning the legality
of the issuance of the securities offered by this prospectus and other legal matters concerning this offering were passed upon for us
by Sullivan &amp; Worcester LLP, New York, New York. Certain legal matters with respect to the legality of the issuance of the securities
offered by this prospectus and other legal matters concerning this offering relating to Israeli law were passed upon for us by Sullivan
&amp; Worcester Tel Aviv (Har-Even &amp; Co.), Tel Aviv, Israel. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <A NAME="a_045"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The consolidated financial statements as of
December 31, 2022 and 2021 and for each of the years in the three-year period then ended incorporated by reference in this prospectus
have been incorporated in reliance on the report of Ziv Haft, Certified Public Accountants, Isr., BDO Member Firm, an independent registered
public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <A NAME="a_046"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENFORCEABILITY
OF CIVIL LIABILITIES</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli
experts named in the registration statement of which this prospectus forms a part, a substantial majority of whom reside outside of the
United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and a substantial
of our directors and officers are located outside of the United States, any judgment obtained in the United States against us or any
of our directors and officers may not be collectible within the United States.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been informed by our legal counsel in Israel, Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), that it may be difficult to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation
of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court
agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable,
the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to specified time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain
exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act
and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which
        the judgment is given and the rules of private international law currently prevailing in Israel;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        judgment is final and is not subject to any right of appeal;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
        service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her
        evidence;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        liabilities under the judgment are enforceable according to the laws of the State of Israel and the judgment and the enforcement
        of the civil liabilities set forth in the judgment is not contrary to the law or public policy in Israel nor likely to impair
        the security or sovereignty of Israel;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
        judgment was not obtained by fraud and does not conflict with any other valid judgments in the same matter between the same parties;</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
        action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted
        in the foreign court; and</FONT> </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the judgment is enforceable according to the laws
    of Israel and according to the law of the foreign state in which the relief was granted.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into
non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a
non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange
in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of
the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus interest at the annual
statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <A NAME="a_047"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have filed with the SEC a registration statement
on Form&nbsp;F-1 under the Securities Act relating to the IPO. This prospectus does not contain all of the information contained in the
registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included
in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document
are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents.
If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description
of its terms. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC are also available to the public through the SEC&rsquo;s website at www.sec.gov. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those
requirements are filing reports with the SEC. Those other reports or other information may be inspected without charge at the locations
described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual,
quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act. However, we will file with the SEC, within 120&nbsp;days after the end of each fiscal year, or such
applicable time as required by the SEC, an annual report on Form&nbsp;20-F containing financial statements audited by an independent
registered public accounting firm, and will submit to the SEC, on Form&nbsp;6-K, unaudited quarterly financial information.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at <FONT STYLE="background-color: white">www.wearabledevices.co.il</FONT>. Information contained on, or
that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website
under applicable corporate or securities laws and regulations, including, posting any XBRL interactive financial data required to be
filed with the SEC and any notices of general meetings of our shareholders.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><A NAME="d_001"></A>INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> The SEC allows us to &ldquo;incorporate by reference&rdquo;
information into this prospectus, which means that we can disclose important information to you by referring you to other documents which
we have filed or will file with the SEC.&nbsp;We are incorporating by reference in this prospectus the documents listed below and all
amendments or supplements we may file to such documents, as well as any future filings we may make with the SEC on Form&nbsp;20-F under
the Exchange&nbsp;Act before the time that all of the securities offered by this prospectus have been sold or de-registered: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> This prospectus incorporates by reference the
documents listed below: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"> (1) </TD><TD STYLE="text-align: left"> Our Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1887673/000121390023022124/f20f2022_wearable.htm" STYLE="-sec-extract: exhibit">Form&nbsp;20-F</A>
                                            for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March 22, 2023; and </TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"> (2) </TD><TD STYLE="text-align: left"> The
                                            description of our securities contained in our Registration Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1887673/000121390022055087/ea165606-8a12b_wearable.htm">Form&nbsp;8-A</A> filed
                                            with the SEC on September 9, 2022, including any amendments and reports filed for the purpose
                                            of updating such description. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> In addition, all subsequent annual reports on
Form&nbsp;20-F filed prior to the termination of this offering and any reports on Form&nbsp;6-K subsequently submitted to the SEC or
portions thereof that we specifically identify in such forms as being incorporated by reference into the registration statement of which
this prospectus forms a part, shall be considered to be incorporated into this prospectus by reference and shall be considered a part
of this prospectus from the date of filing or submission of such documents. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> As you read the above documents, you may find
inconsistencies in information from one document to another. If you find inconsistencies between the documents and this prospectus, you
should rely on the statements made in the most recent document. All information appearing in this prospectus is qualified in its entirety
by the information and financial statements, including the notes thereto, contained in the documents incorporated by reference herein. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"> We will provide to each person, including any
beneficial owner, to whom this prospectus is delivered, a copy of these filings, at no cost, upon written or oral request to us at the
following address: 5 Ha-Tnufa Street, Yokne&rsquo;am Illit, 2066736, Israel, Attention: Chief Financial Officer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Wearable Devices Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;,
2023</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>PART II</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>&nbsp;</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>INFORMATION NOT REQUIRED IN PROSPECTUS</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors,
Officers and Employees</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Indemnification</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Israeli Companies Law 5759-2999, or Companies
Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder against
the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking
made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor
    of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement
    or arbitrator&rsquo;s award approved by a court; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo;
    fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority
    authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed
    against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the
    criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding,
    or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent;
    or (b) in connection with a monetary sanction; </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo;
    fees, expended by the office holder or imposed on him or her by a court; (1) in proceedings that the company institutes, or that
    another person institutes on the company&rsquo;s behalf, against him or her; (2) in a criminal proceeding of which he or she was
    acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection
    with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&rsquo;
    fees. An &ldquo;Administrative Procedure&rdquo; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli
    Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement
    to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Companies Law also permits a company to
undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him
or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount or criterion: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> &#9679; &nbsp; </TD>
    <TD> to events that in the opinion of the board of directors can be foreseen based on the company&rsquo;s activities at the time
    that the undertaking to indemnify is made; and &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &#9679; &nbsp; </TD>
    <TD> in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to
    be reasonable under the circumstances. &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have entered into indemnification agreements
with all of our directors and with all members of our senior management. Each such indemnification agreement shall provide the office
holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not
covered by directors and officers insurance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Exculpation</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Under the Companies Law,
an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but may exculpate in
advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result
of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exculpation
is included in its articles of association. Our amended and restated articles of association provide that we may exculpate, in whole or
in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty of care,
but prohibit an exculpation from liability arising from a company&rsquo;s transaction in which our controlling shareholder or officer
has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release our office
holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by
law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Limitations</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would
provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty
of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable
basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was
carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive
an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> <FONT STYLE="background-color: white">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our amended and restated articles of association
permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent permitted
or to be permitted by the Companies Law. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Item&nbsp;7. Recent Sales of Unregistered Securities </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Set forth below are the sales of all securities
by the Company since March 2020, which were not registered under the Securities Act. The Company believes that each of such issuances
was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation
S under the Securities Act.&nbsp; The conversions described below were exempt from registration under Securities Act in reliance on Section
3(a)(9) of the Securities Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> In April 2021, the Company converted all of
the above convertible securities into an aggregate of 3,081,102 ordinary shares, NIS 0.01 par value per share, or the Ordinary Shares. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> In April 2021, we issued to a group of investors
1,343,374 Ordinary Shares and warrants to purchase 671,687 Ordinary Shares, at an exercise price of 125% of the per share purchase price
in an initial public offering, for a total consideration of $3.025 million. Prior to the issuance, (i) we converted each one of our issued
and outstanding ordinary A shares into one Ordinary Share; (ii) reclassified our authorized share capital of 2,000,000 ordinary A shares
into 2,000,000 Ordinary Shares; (iii) increased our authorized share capital by 10,000,000 Ordinary Shares; and (iv) increased the number
of Ordinary Shares under our 2015 Share Option Plan, or the 2015 Plan, by an additional 200,000 Ordinary Shares. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> In November 2021, we issued warrants to purchase
up to 22,205 Ordinary Shares, issued to a consultant, at an exercise price of $2.25 per share to a consultant, which all are vested as
of March 30, 2023. In September 2022, we issued warrants to purchase up to 23,640 Ordinary Shares, issued to an advisor, at an exercise
price of $4.23 per Ordinary Share. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2022, we began entering into certain
simple agreements for future equity, or the SAFEs, for aggregate proceeds of up to $3 million, of which we received $500 thousand under
the SAFEs. Any amounts received under the SAFEs we enter into will be automatically converted into our Ordinary Shares in the event we
close an Equity Financing (as defined hereinafter) at a discount of 20% from the per share purchase price in such Equity Financing. An
Equity Financing is a transaction or series of transactions with the principal purpose of raising capital in an aggregate amount of at
least $5,000,000, excluding all outstanding (i) SAFEs, and (ii) other convertible securities (if any), pursuant to which we issue and
sell Ordinary Shares at a fixed pre-money valuation. In case of an initial public offering or a Change of Control transaction (as defined
hereinafter), the SAFE amount shall, at the election of the investor thereunder, either (i) convert into our Ordinary Shares at a discount
of 20% from the per share price at such event, or (ii) be repaid to the investor (subject to adjustments in case there are insufficient
funds for such repayment to all SAFE investors) at the closing thereof. The conversion of the SAFE amounts into the Ordinary Shares in
case of an initial public offering, is also subject to certain lock-up periods and other restrictions on transfer. In the event of a
dissolution event (e.g., a voluntary or involuntary termination of operations, dissolution or our winding-up), the SAFE amount shall
be repaid to the investors prior to or concurrently with the consummation of such an event. In addition, we agreed to issue to each SAFE
investor a warrant to purchase our Ordinary Shares with an exercise price equal to 150% of the public offering price in such offering
for an aggregate amount of up to 25% of such investor&rsquo;s SAFE amount. The warrants shall be exercisable until the earlier of: (i)
eighteen (18) months from January 2022; or (ii) in a Change of Control event, which generally covers (a) transaction in which any person
or group becomes the beneficial owner, directly or indirectly, of more than 50% of our outstanding voting securities with the right to
vote for the election of members of our board of directors, or (b) any reorganization, merger or our consolidation, or (c) a sale, lease
or other disposition of all or substantially all of our assets. Following the consummation of our IPO, $100 thousand received under the
SAFEs were &nbsp;repaid in cash and $400 thousand were converted into 118,204 Ordinary Shares, based on the IPO price of $4.23 per Ordinary
Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> In February 2023, we issued a total of 169,125
Ordinary Shares to Alpha Capital Anstalt, or Alpha, and certain other investors pursuant to the terms of their April 2021 share purchase
agreements with us, as amended by the June 2022 written consent with Alpha. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Since March 2020, we have granted to our directors,
consultants and service providers, officers, and employees options to purchase an aggregate of 654,090 Ordinary Shares under our 2015
Plan, with an exercise prices ranging between $0.003 and $2.251 per share. As of March 30, 2023, 372,771 options granted to directors,
officers and employees were exercised, and 128,163 options forfeited, such that the total outstanding amount of options to directors,
officers and employees as of March 30, 2023 is 1,247,689. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Item&nbsp;8. Exhibits and Financial Statement Schedules </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Exhibits:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
    Number</B></FONT> </TD>
    <TD STYLE="vertical-align: top; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;Description</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022058006/ea165832ex1-1_wearable.htm">Form of Underwriting Agreement by and among Wearable Devices Ltd. and the underwriters named therein (filed as Exhibit 1.1 to Form 6-K (File No. 001-41502) filed on September 22, 2022 and incorporated herein by reference).</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1887673/000121390022012239/ea156798ex3-2_wearable.htm">Amended and Restated Articles of Association of Wearable Devices Ltd.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022018390/ea157448ex4-1_wearable.htm">Form of Representative&rsquo;s Warrant.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022019279/ea158314ex4-3_wearable.htm">Form
    of Warrant Agent Agreement.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022058006/ea165832ex4-1_wearable.htm">Form of Warrant (filed as Exhibit 4.1 to Form 6-K (File No. 001-41502) filed on September 22, 2022 and incorporated herein by reference).</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022054088/ea164883ex5-1_wearabledev.htm">Opinion
    of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Israeli counsel to Wearable Devices Ltd.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022054088/ea164883ex5-2_wearabledev.htm">Opinion
    of Sullivan &amp; Worcester LLP, U.S counsel to Wearable Devices Ltd.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022012239/ea156798ex10-1_wearable.htm">Form
    of Indemnification Agreement.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022008340/ea155863ex10-2_wearable.htm">Wearable
    Devices Ltd. 2015 Share Option Plan.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022018390/ea157448ex10-3_wearable.htm">Share
    Purchase Agreement, dated April 22, 2021, by and between Wearable Devices Ltd. and Alpha Capital Anstalt.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4* #</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022018390/ea157448ex10-4_wearable.htm">Agreement,
    dated July 16, 2020, by and between Wearable Devices Ltd. and the Israeli Innovation Authority.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022012239/ea156798ex10-5_wearable.htm">Compensation
    Policy.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022040341/ea163052ex10-6_wearabledev.htm">Senior
    Credit Facility Agreement, dated July 4, 2022, by and between Wearable Devices Ltd. and L.I.A. Pure Capital Ltd.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022040341/ea163052ex10-7_wearabledev.htm">Consent
    of Alpha Capital Anstalt, dated June 27, 2022.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022040341/ea163052ex10-8_wearabledev.htm">First
    Addendum to Senior Agreement, dated July 19, 2022, by and between Wearable Devices Ltd. and L.I.A. Pure Capital Ltd.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022008340/ea155863ex21-1_wearable.htm">Subsidiaries
    of Wearable Devices Ltd.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea176025ex23-1_wearabledev.htm">Consent of Ziv Haft, Certified Public Accountants, Isr., BDO member firm, an independent registered public accounting firm.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022054088/ea164883ex5-1_wearabledev.htm">Consent
    of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.) (included in Exhibit 5.1)</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022054088/ea164883ex5-2_wearabledev.htm">Consent
    of Sullivan &amp; Worcester LLP (included in Exhibit 5.2)</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022060689/ea166589-posam_wearabledev.htm#p_001">Power of Attorney.</A></FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1887673/000121390022054088/ea164883ex-fee_wearabledev.htm">Filing
    Fee Table</A></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </FONT> </TD>
    <TD STYLE="width: 97%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed.</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">** </FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#&nbsp; </FONT> </TD>
    <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain schedules and
    exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any
    omitted schedule or exhibit to the SEC upon request. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Financial Statement Schedules:</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> All financial statement schedules have been
omitted because either they are not required, are not applicable or the information required therein is otherwise set forth in the Company&rsquo;s
financial statements and related notes thereto. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Item&nbsp;9. Undertakings</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (a) The undersigned Registrant hereby undertakes: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file, during any period in which offers or sales
    are being made, a post-effective amendment to this registration statement: </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any prospectus required by section 10(a)(3)
    of the Securities Act of 1933; </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To reflect in the prospectus any facts or events
    arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
    or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the
    foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
    that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in
    the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
    no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table
    in the effective registration statement; </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To include any material information with respect
    to the plan of distribution not previously disclosed in the registration statement or any material change to such information in
    the registration statement. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining any liability
    under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating
    to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
    thereof. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To remove from registration by means of a post-effective
    amendment any of the securities being registered which remain unsold at the termination of the offering. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To file a post-effective amendment to the registration
    statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout
    a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished,
    provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant
    to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current
    as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a
    post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act
    or Item 8.A of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished to
    the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated
    by reference in the Form F-3. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability under
    the Securities Act of 1933 to any purchaser: </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is relying on Rule 430B: </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus filed by the registrant pursuant
    to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of
    and included in the registration statement; and </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each prospectus required to be filed pursuant to
    Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant
    to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act
    of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus
    is first used after effectiveness of the date of the first contract or sale of securities in the offering described in the prospectus.
    As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date and underwriter, such date shall
    be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which
    that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement
    or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part
    of the registration statement will, as to a purchaser with a time of contract sale prior to such effective date, supersede or modify
    any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any
    such document immediately prior to such effective date; or </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the registrant is subject to Rule 430C, each
    prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
    relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the
    registration statement as of the date it is first used after effectiveness. <I>Provided, however</I>, that no statement made in a
    registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated
    by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
    a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement
    or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
    </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, for the purpose of determining liability of
    the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant
    undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless
    of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
    by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered
    to offer or sell securities to such purchaser: </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The portion of any other free writing prospectus
    relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf
    of the undersigned registrant; and </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising
    under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the
    foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
    such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
    for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
    officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
    director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
    of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
    such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such
    issue. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes that:
    </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 28.35pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That for purposes of determining any liability under
    the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance
    upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4), or 497(h)
    under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: 28.35pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That for the purpose of determining any liability
    under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
    statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
    initial&nbsp;bona fide&nbsp;offering thereof. </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"> <B></B> </P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>SIGNATURES</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> Pursuant to the requirements of the Securities
Act of&nbsp;1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto duly
authorized, in Yokne&rsquo;am Illit, Israel, on March 30, 2023. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WEARABLE
    DEVICES LTD.</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 3%; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 35%; text-align: justify"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT> </TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Asher Dahan </FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> &nbsp; </TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asher
    Dahan </FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the Securities
Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following persons in the capacities and
on the dates indicated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 25%"> <B>Signature </B>&nbsp;&nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 37%"> <B>Title</B>&nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 36%"> <B>Date</B>&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> /s/ Asher Dahan&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Chief Executive Officer, Director&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 30, 2023&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> Asher Dahan &nbsp;&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> (Principal Executive Officer)&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> /s/ Alon Mualem&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Chief Financial Officer&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 30, 2023&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: black 1.5pt solid"> Alon Mualem&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> (Principal Financial and Accounting Officer)&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> *&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Director&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 30, 2023&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> Eli Bachar &nbsp;&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"> *&nbsp; </TD>
    <TD> &nbsp;Director&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 30, 2023&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> Yaacov Goldman&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> *&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Director&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 30, 2023&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> Ilana Lurie &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"> *&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> Director&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> March 30, 2023&nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> Guy Wagner&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%"> <FONT STYLE="font-size: 10pt">*By:</FONT> </TD>
    <TD STYLE="width: 26%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-size: 10pt">/s/ Asher Dahan</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 30%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 36%; text-align: center"> <FONT STYLE="font-size: 10pt">March 30, 2023</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-size: 10pt">Name:</FONT> </TD>
    <TD> <FONT STYLE="font-size: 10pt">Asher Dahan</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-size: 10pt">Title:</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-size: 10pt">Attorney-in-fact</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN
THE UNITED STATES</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the Securities Act of 1933, as
amended, the undersigned, Mudra Wearable, Inc., the duly authorized representative in the United States of Wearable Devices Ltd., has
signed this registration statement on March 30, 2023. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 60%; padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mudra Wearable, Inc. </FONT> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mudra Wearable, Inc.
    </FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"> &nbsp; </DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&nbsp;</B> </P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ea176025ex23-1_wearabledev.htm
<DESCRIPTION>CONSENT OF ZIV HAFT, CERTIFIED PUBLIC ACCOUNTANTS, ISR., BDO MEMBER FIRM, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><IMG SRC="ex23-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Consent of Independent Registered
Public Accounting Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wearable Devices Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We hereby consent to the incorporation by reference
in this Post- Effective Amendment No. 2 to the Registration Statement on form F-1 of Wearable Devices Ltd. of our report dated March 21,
2023, relating to the consolidated financial statements which appears in Wearable Devices Ltd.&rsquo;s Annual Report on Form 20-F for
the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We also consent to the reference to us under the
caption &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Ziv Haft</TD>
  <TD STYLE="width: 60%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Ziv Haft</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Certified Public Accountants (Isr.)</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>BDO Member Firm</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">March 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex23-1_002.jpg" ALT="">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% ',# 2(  A$! Q$!_\0
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MO9:]I<6H:?,9;:7(!*E2"#@J0>00000:\WT3PYK]]8>)9M*\07^EW#:M=^1
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MWTP?TJGX?MKJ4SZMJ5NUM?7F!Y#,&-O$OW8\CC/5CCNWM5>'1I[O3O$EC.#
M+Z[E,3GG*F- &QZ9!_*@"U#K%_=JD]MHL[6CX*O)*D;LI_B"'I^)!]JFO]6F
MM]1AL+6QDN9Y(6F.)%0*H('4]\L*A@U>]CA$-WHUXMTH"MY 5XF/JK;AQ]<&
MJ>MV@E\16EW/IMW=6RVDD?\ HYY5RZ'G##L#0!J/JLEIIEU?:C9O:I;J7*AQ
M(6 &>,46FH:E-,BW&CM!"_207"/M_P!X#^F:BLI(UTN>*#2;M5C!Q;S@ RYZ
M@%F(/XFLJ&V=+^T_L73M1L )@;A93LMQ'_$-A)!/IM'7OB@#KZ*** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  S ' # 2(  A$! Q$!_\0
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H&G^XFW+LUH;E%%%:GF!1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex23-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !? K(# 2(  A$! Q$!_\0
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M3E6H1<H^S7.I1?/&-2\)Q:M%-M0DX2NI)\RWLFTG\P0_\$[_ (T>!OAW\/\
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M%JKNW:[TOJEI]1P3_O'&2=K?\0J\3+ZZ)+(LCN]7;1*]W96W:1]WZ7Q%&3@
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M(?#_ .)L]CI/AZP\>_"G6M,\02:;<>"_'/B#Q?X[\2W.I^(M'U7P%>?"^_\
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ML&$BZU&W>W:&]NL6\ %U<(\Z^1#B3"*!KE#&DO+2%DSTQD_-G&P#DG)XP<D
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M&_C5!\2M;MM1BO#/J^EQ>'M9T1].TIK:*2-+X3:O'.&NV2)DB= VXX7N+O\
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M]MV:S:=??ONHCEY69V4!2.25^8D;EZC(7(.#D=P2P)4*AY6=^1D@.QP3O .
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M_P#\3SQ]9ZIJ][-J.KP7L+P8?_!2KPMXB\5?$G5O"NEW7C^TLOB'^QUX_P#
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MPGXZEMH=5%O#96.CV?B+4-6\*>'/"YN%&D_"R-O#T$+V-J\I_4\"#Y0)3RP
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M3VRO4DH.*G5J5$Y5(RG%24%%2E3H8>G.?+33<X8>A%\S2HP48H_G]\,O\?\
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MW/9IX3":S/HHD0M^T/K/Q)U/Q'I4?Q=U/]K[PE\._P!OU=2T3Q'8>.O^%3>
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M>W^J&T^'SGE/G><T8B,I8!Y8]AB(9Q&"[.&4,)&P1C*XRE:D$,42X5P0RQ
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M\\+_ +*?@#X\OX@N?!_CZ'7]5\6_$?Q'\2/#^G>'K;P;*RR:?I'AI?A_#?\
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M/P7N-)\(70@NM7O;W2_%6G_%NYN;;7[3PW8V-M)X5U&QT^?Q#?V^HVFG^Z^
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MM/\ %>N>(Y/'PU1_$>GS1BSDE?V7Q=^U7%X4EBUZ'X7ZCK/PXT[P;\)_'7Q
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M?:+XO\->+O&UO#93Z=;>"OC)JFI3:'X'FT:.;4&,VEN!J%Y)K&G:+]&_ O\
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M$K0/#VM:1J^LW^D'7K>QO_ $<GB/1].\/:OJFB6&M:9J6LOH]AJNCSWL5_\
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MU[XA7=_XVU;6=:>?7;OQ%J^NW#:D+;7-8MKSZDQ_//Z8_E_CUI-H!!&1@
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MV9AK> /V>_AG\-;WP]JGAK2]<?6_#MM\0(H]?UWQ7XD\2:YK5[\6-8\,:_\
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@:A>_.>3U'3DC'O@@X]OSIU-)+96!7MJ[ON%%%%,#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
